357916-36-0

Upstream product

• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 648930-80-7 (2S,3R)-3-aminopyrrolidine-1,2-dicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 595579-93-4 (1S,5R)-7-Oxo-2,6-diaza-bicyclo[3.2.0]heptane-2,6-dicarboxylic acid 2-benzyl ester 6-tert-butyl ester 
• 214837-30-6 benzyl (1S,4S,5S)-6-(3,4-dimethoxybenzyl)-7-oxo-4-<(trifluoromethyl)sulfonyloxy>-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 
• 145574-13-6 benzyl (1S,4S,5S)-6-(3,4-dimethoxybenzyl)-4-hydroxy-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 
• 145574-15-8 benzyl (1S,5R)-6-(3,4-dimethoxybenzyl)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 
• 145574-16-9 benzyl (1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 

Relevant academic research and scientific papers

A virosome-mimotope approach to synthetic vaccine design and optimization: Synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate

An optimized cyclic peptidomimetic (see picture) of the NPNA-repeat region in the circumsporozoite (CS) protein of P. falciparum was designed. When delivered to the immune system on human-compatible viruslike particles (virosomes), the mimetic effectively

BIOLOGICALLY ACTIVE COMPOUNDS

Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8/sup